Neurosense Therapeutics is trading at $3.78, up +9.68%; coverage does not directly tie the gain to a catalyst. - The company announced October 13 that its Nasdaq Hearings Panel hearing is scheduled for November 10; its appeal stays suspension and delisting while the Panel considers its case. - It says it regained the $1.00 minimum bid-price requirement. A Roth Capital downgrade cited a delayed Phase 3 study; indexes are mixed, with no broad same-direction move above 0.5%.